Healome Therapeutics
Develops proprietary eye-drop matrix technology for ocular surface diseases
£2MSeed
Role not disclosedLoading investors…
Activity from announced rounds
Develops proprietary eye-drop matrix technology for ocular surface diseases
Develops AI-based predictive genomics approach to target discovery